EGB Ventures follows a clearly defined and structured process
We identify high-potential opportunities through our global network of clinicians, scientists and research institutions. Every concept is assessed against clear criteria: unmet medical need, sound science and a credible path to market. We engage directly with key opinion leaders, patient advocate and strategic partners to test each opportunity’s clinical rationale, feasibility and commercial potential.
Many of our portfolio companies have been established based on intellectual property (IP) developed by founder, William Garner, MD.
Once validated, we structure and establish new companies around the opportunity - recruiting experienced leadership, securing intellectual property, and defining development and regulatory strategies.
We are deeply committed to our portfolio companies and, in most cases, provide support and financing through to listing or exit.
We invest alongside trusted partners who share our patient-first and performance-driven philosophy. Together, we provide the strategic capital and operational guidance needed to progress programs efficiently through preclinical and clinical milestones.
We actively manage our portfolio to ensure disciplined progress and capital efficiency. Value realisation may occur through partnerships, licensing or public market entry - with the overarching aim of delivering both patient impact and sustainable investor returns.